FFN
KLRS

Focus Financial Network’s Kalaris Therapeutics KLRS Stock Holding History

Focus Financial Network’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,397
Closed -$21.8K – 774
2023
Q4 		$21.8K Buy
+1,397
New +$55.1K ﹤0.01% 706
2022
Q1 		– Sell
-1,093
Closed -$325K – 620
2021
Q4 		$325K Hold
1,093
– – 0.05% 280
2021
Q3 		$630K Hold
1,093
– – 0.08% 212
2021
Q2 		$496K Buy
1,093
+9
+0.8% +$4.65K 0.07% 264
2021
Q1 		$584K Buy
+1,084
New +$911K 0.07% 233

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Focus Financial Network's KLRS Position: Q1 2024 in Review

Focus Financial Network sold out of Kalaris Therapeutics (KLRS) in Q1 2024, closing a stake of 1,397 shares — an estimated $21.8K sold.

Focus Financial Network first reported a position in KLRS in Q1 2021 and held it in 5 quarters. The position peaked at $630K in Q3 2021. 76 funds tracked by Wall St. Rank hold KLRS as of Q1 2024.

  • Focus Financial Network reported no remaining Kalaris Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Focus Financial Network sold 1,397 Kalaris Therapeutics shares in Q1 2024, an estimated $21.8K.
  • Focus Financial Network first reported a position in Kalaris Therapeutics in Q1 2021 and held it in 5 quarters.
  • Focus Financial Network's Kalaris Therapeutics position peaked at $630K in Q3 2021.
  • 76 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2024.

Based on Focus Financial Network's 13F filing for Q1 2024, filed 24 Apr 2024.